Skip to main content

Table 4 In vitro susceptibility to various antifungal agents of selected Candida species causing invasive candidiasis in neonatal versus non-neonatal pediatric patients

From: Comparison of the incidence, clinical features and outcomes of invasive candidiasis in children and neonates

  All Candida (total n = 295) C. albicans C. parapsilosis Other Candida spp.
All episodes Neonates Children Neonates Children Neonates Children Neonates Children
Fluconazole
 Susceptible 251 (85.1) 87 (83.7) 164 (85.9) 47 (97.9) 73 (94.8) 30 (100) 59 (100) 10 (38.5) 32 (58.2)
 S-DD or R 44 (17.5) 17 (16.3) 27 (14.1) 1 (2.1) 4 (5.2) 0 (0) 0 (0) 16 (61.5) 23 (41.8)
Voriconazole
 Susceptible 262 (88.8) 97 (93.3) 165 (86.4) 47 (97.9) 73 (94.8) 30 (100) 59 (100) 20 (76.9) 33 (60)
 S-DD or R 33 (11.2) 7 (6.7) 26 (13.6) 1 (2.1) 4 (5.2) 0 (0) 0 (0) 6 (23.1) 22 (40)
Amphotericin B
 Susceptible 292 (99.0) 104 (100) 188 (64.6) 48 (100) 77 (100) 30 (100) 59 (100) 26 (100) 52 (94.5)
 S-DD or R 3 (1.0) 0 (0) 3 (1.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 3 (5.5)
Micafungin
 Susceptible 291 (98.6) 102 (98.1) 189 (99.0) 48 (100) 76 (98.7) 28 (93.3) 58 (98.3) 26 (100) 55 (100)
 S-DD or R 4 (1.4) 2 (1.9) 2 (1.0) 0 (0) 1 (1.3) 2 (6.7) 1 (1.7) 0 (0) 0 (0)
Caspofungin
 Susceptible 293 (99.3) 104 (100) 189 (99.0) 48 (100) 77 (100) 30 (100) 59 (100) 26 (100) 53 (96.4)
 S-DD or R 2 (0.7) 0 (0) 2 (1.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (3.6)
  1. All data were expressed as number (percentage %), unless indicated otherwise
  2. S-DD susceptible-dose dependent, R resistant